With a market cap of $101.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a leading U.S.-based biotechnology company ...

Vertex drops aspiring Journavx follower in acute pain after phase 2 failure By Darren Incorvaia Aug 4, 2025 5:34pm Vertex Pharmaceuticals Clinical Trial Results pain failed trials ...

Vertex is severing one of its ties to CRISPR Therapeutics. The big biotech has chosen to opt out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte, leaving ...

A next-generation Vertex Pharmaceuticals pain drug failed to beat a placebo in a Phase 2 clinical trial. Despite the disappointing outcome in bunionectomy pain, the company is continuing ...

After a long development road, the first CRISPR-based gene editing therapy recently cleared a FDA advisory committee and appears to be nearing its U.S. launch. Vertex Pharmaceuticals, awaiting the ...

Doctors protest cost of Vertex cystic fibrosis drug as its scientists prepare to receive $3 million ‘Oscars of Science’ award Vertex disputes critics’ allegations of ‘scandalous’ drug ...

The heritage British brand has been revived by a chairman whose impressive career before watchmaking includes a three-year ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial market ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell- ...

Major AI players are racing to solve a critical challenge: memory. Google’s new Vertex AI Memory Bank lets agents retain long-term context across sessions, while OpenAI, Anthropic, Microsoft, CrewAI ...

Vertex Pharmaceuticals said Monday afternoon that its next-generation non-opioid pain reliever failed to significantly outperform placebo in a Phase 2 trial.

Vertex CEO Reshma Kewalramani, M.D., made $20.6 million in 2023, which was an increase of 30% from her $15.9 million pay in 2022.